117237-99-7

Basic information

• Product Name: 2(1H)-Quinoxalinone,7-methoxy-3-methyl-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,7-methoxy-3-methyl-(9CI);7-METHOXY-3-METHYLQUINOXALIN-2(1H)-ONE
• CAS NO: 117237-99-7
• Molecular Formula: C10 H10 N2 O2
• Molecular Weight: 190.2
• Product Categories: PIPERIDINE
• Mol File: 117237-99-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Quinoxalinone,7-methoxy-3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,7-methoxy-3-methyl-(9CI)(117237-99-7)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,7-methoxy-3-methyl-(9CI)(117237-99-7)

Safety Data

• Hazardous Substances Data: 117237-99-7(Hazardous Substances Data)

Usage

Structure

Quinoxaline derivative with a methoxy group at the 7th position and a methyl group at the 3rd position

Pharmacological applications

Antidiabetic, anti-inflammatory, and anti-cancer agent

Current status

Ongoing research to explore therapeutic potential and safety profile

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 95-54-5 1,2-diamino-benzene 
• 61324-93-4 1-fluoro-nitro-4-methoxybenzene 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 600-22-6 pyruvic acid methyl ester 
• 1427029-09-1 7-methoxy-3-methyl-3,4-dihydro-1H-quinoxalin-2-one 
• 1427029-08-0 methyl-2-[(4-methoxy-2-nitrophenyl)amino]propanoate 
• 879125-27-6 N-(4-methoxy-2-nitro-phenyl)-alanine 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 127-17-3 2-oxo-propionic acid 
• 917343-58-9 3-chloro-6-methoxy-2-methylquinoxaline 

Downstream Products

• 1417408-94-6 1-(2-chlorophenyl)-8-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 

Relevant articles and documents

Unexpected imidazoquinoxalinone annulation products in the photoinitiated reaction of substituted-3-methyl-quinoxalin-2-ones with N-phenylglycine

Photoinduced electron transfer between N-phenylglycine (NPG) and electronically excited triplets of 7-substituted-3-methyl-quinoxalin-2-ones in acetonitrile generate the respective ion radical pair, where by decarboxylation the phenyl-amino-alkyl radical, PhNHCH2?, is generated. This radical reacts with the 3-methyl-quinoxalin-2-ones ground states, leading to the product 2. Other, unexpected, 7-substituted-1,2,3,3a-tetrahydro-3a-methyl-2- phenylimidazo[1,5-a]quinoxalin-4(5H)-ones, annulation products, 3a-f, were generated; likely by the addition of two PhNHCH2? radicals, to positions 3 and 4 of the quinoxalin-2-ones. The reaction mechanism includes a photoinduced one electron transfer initiation step, propagation steps involving radical intermediates and NPG with radical chain termination steps that lead to the respective products 2a-f and 3a-f and NPG by-products. The proposed mechanism accounts for the strong dependency found for the initial photoconsumption quantum yields on the electron-withdrawing power of the substituent. Therefore, photolysis of common reactants widely used such as NPG and substituted quinoxalin-2-ones may provide a simple synthetic way to the unusual, unreported tetrahydro-imidazoquinoxalinones 3a-f.

Iron- or Zinc-Mediated Synthetic Approach to Enantiopure Dihydroquinoxalinones

A general and efficient synthesis of enantiopure dihydroquinoxalinones has been developed using naturally occurring amino acids as starting materials. The reductive cyclization of N-(o-nitroaryl)amino esters was performed by using iron and zinc metal under mild conditions in a water/ethyl acetate mixture. The corresponding dihydroquinoxalinones were obtained in moderate to high yields and high enantiomeric purity, among which 7 new compounds were unprecedented in the literature.

HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.